TG THERAPEUTICS, INC.
No enriched coverage for $TGTX in the last 7 days.
No SEC Form 4 filings for $TGTX in the last 30 days.
See all $TGTX insider activity →TG Therapeutics said Q2 2026 results reflected record new patient starts and broader physician adoption of BRIUMVI. The company raised full-year 2026 U.S. BRIUMVI net revenue guidance to $890 million to $905 million and expects about $950 million global revenue. It reported $55 million in R&D charges tied to subcutaneous manufacturing and cited Phase III data for a 600 mg single-infusion schedule.
TG Therapeutics (TGTX) shares fell about 11% the day after earnings, as profit declined despite growth tied to BRIUMVI. The company reported Q2 2026 revenue of about $240.3M (up from $141.1M) and BRIUMVI revenue of about $228M, but net income fell to $7.8M and EPS to just over $0.05. Management cited manufacturing charges.
TG Therapeutics Inc. (TGTX) reported Q2 net income of $7.8 million, or 5 cents per share, below Wall Street expectations of 41 cents per share, according to Zacks. Revenue was $240.3 million, above the $230.9 million forecast. The company expects full-year revenue of $950 million.
Recent TGTX coverage spans earnings, financial news and regulation.
Guidance raise and clearer subcutaneous roadmap (single-infusion schedule, DTC push) are likely to support near-term sentiment and valuation multiples.
Earnings show margin pressure from manufacturing charges, increasing uncertainty around the durability of BRIUMVI-driven profitability.
Earnings missed on EPS while revenue topped forecasts, with a specific full-year revenue expectation provided.
Revenue rose sharply, but GAAP earnings fell, creating a mixed signal for near-term sentiment and valuation.
The guidance raise and revenue beat were not enough to offset valuation expectations, implying near-term downside risk until management clarifies demand and Phase 3 timing.
alphai scores every news story that mentions TGTX with an AI model for sentiment and relevance, and aggregates insider trades from TG THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TG Therapeutics said Q2 2026 results reflected record new patient starts and broader physician adoption of BRIUMVI. The company raised full-year 2026 U.S. BRIUMVI net revenue guidance to $890 million to $905 million and expects about $950 million global revenue. It reported $55 million in R&D charges tied to subcutaneous manufacturing and cited Phase III data for a 600 mg single-infusion schedule.
5 min readTG Therapeutics (TGTX) shares fell about 11% the day after earnings, as profit declined despite growth tied to BRIUMVI. The company reported Q2 2026 revenue of about $240.3M (up from $141.1M) and BRIUMVI revenue of about $228M, but net income fell to $7.8M and EPS to just over $0.05. Management cited manufacturing charges.
4 min readTG Therapeutics Inc. (TGTX) reported Q2 net income of $7.8 million, or 5 cents per share, below Wall Street expectations of 41 cents per share, according to Zacks. Revenue was $240.3 million, above the $230.9 million forecast. The company expects full-year revenue of $950 million.
3 min readTG Therapeutics (TGTX.OB) reported Q2 results. Net income fell to $7.78 million, or $0.05 per share, from $28.19 million, or $0.17 per share, a year earlier. Revenue rose 70.3% to $240.33 million from $141.15 million. Full-year revenue guidance is $890 million to $905 million.
2 min readInvesting.com reports TG Therapeutics (TGTX) shares fell about 4.7% pre-open to $49.60 after its Q2 2026 results. The company said revenue was $240.3M versus ~$228.85M expected, and it raised FY2026 global revenue to about $950M and Briumvi U.S. net product revenue guidance to $890M-$905M. Despite beats, the market had priced in strong growth.
3 min readTG THERAPEUTICS, INC. (TGTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_997107.htm EXHIBIT 99.1 ex_997107.htm Exhibit 99.1 TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI ® Revenue Guidance Second quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue o
6 min readAustralia’s health minister Mark Butler said an expert panel will keep MS drugs Ocrevus, Kesimpta and Lemtrada on the PBS, maintaining taxpayer subsidies after manufacturers sought higher payments. The PBAC also ordered a rapid review of MS drug use to be completed by year end. The article cites possible price cuts tied to US “Most Favoured Nation” policy and PBS reference pricing.
7 min readClearBridge’s Q2 2026 SMID Cap Growth Strategy said small and mid-cap growth stocks rose, but its fund lagged the Russell 2500 Growth Index. In the letter, it cited TG Therapeutics (NASDAQ:TGTX) as a top contributor after Briumvi’s growth exceeded expectations and positive clinical data supported a subcutaneous version. TGTX closed July 10 at $57.12.
2 min readThe article profiles five biotech/healthcare stocks and cites recent catalysts and upcoming events. Glaukos (GKOS) highlights Epioxa launch and raised 2026 sales guidance ahead of Q2 2026 results July 29, 2026. TG Therapeutics (TGTX) cites BRIUMVI trial updates and Q2 results early August. Corcept (CORT) points to Lifyorli progress and raised guidance. Relay (RLAY) and Nutex Health (NUTX) note Phase 3 and upcoming quarterly results. It lists large post-publication price gains for each.
7 min readThe Motley Fool highlights Incyte (INCY) and TG Therapeutics (TGTX) as growth biotech stocks. For Incyte, it cites Q1 Jakafi sales of $758M (+7% YoY), Opzelura sales of $143M (+20%), revenue of $1.27B (+21%), and adjusted EPS $1.81 vs $1.34 consensus, plus a $1.25B Vega Therapeutics acquisition. For TG, it notes Briumvi U.S. sales of $194.8M in Q1 and raised full-year revenue guidance to $925M.
6 min read
